Understanding ALK Fusions in NSCLC

In this episode of Lung Cancer Considered, Dr. Sai-Hong Ignatius Ou shares his career growth and experience participating and leading breakthrough clinical trials on therapies to treat ALK positive patients with lung cancer. Dr. Ou discusses a pivotal moment at the beginning of his career when he visited the Pfizer campus in California to learn about their effort to develop a phase 1 trial examining MET amplifications and MET mutations. The visit helped spur him to become more involved in lung cancer research.